Weight-loss drugs get remarketed from medical treatment to lifestyle product

Novo Nordisk and Eli Lilly shift GLP-1 marketing away from obesity-as-illness toward looking and feeling better generally, as prices fall and access widens.

nextRadar catches the comfort read before the study names it AI-doom rhetoric completes its trip from press tour to punchline Food's climate stays quiet while the sweep carries a genuine regulatory first

more today's cover the room, every day how we read culture what runs, and what does not

131 of 208 sources reporting
counted 18:53 UTC